tradmap

VIVS VivoSim Labs, INC.

$1.13 -2.59%

Healthcare · Biological Products, (No Diagnostic Substances)

VivoSim Labs, INC. (VIVS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3 million. Shares last traded at $1.13, 79.3% below their 52-week high. Over the past year the stock is down 36.5%. Net profit margin is -1727.8%, below the peer median of 6.3%. Revenue grew 32.1% year over year.

Market Cap
$3M
Shares Out
2.6M
EPS (TTM)
$-12.99
P/E Ratio
P/S Ratio
20.47
P/B Ratio
0.66
Dividend / Share
Dividend Yield
52-Week High
$5.46
52-Week Low
$1.13
Volume
1,639
Avg Vol (3m)
1,469.937

Performance

1W
-3.83%
1M
-11.37%
3M
-37.91%
6M
-48.17%
YTD
-39.57%
1Y
-36.52%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
34.55
SMA (50)
$1.36
SMA (200)
$2.10
Price vs SMA50
-16.79%
Price vs SMA200
-46.21%
ATR (14)
$0.05

Financials

Revenue
$0M
Net Income
$-2M
Gross Margin
Operating Margin
-8761.1%
Net Margin
-1727.8%
Return on Equity
-56.0%
Return on Assets
-35.7%
Current Ratio
2.44
Debt / Equity
0.57
Revenue Growth (YoY)
+32.1%

Latest reported annual period ending 2025-03-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q3 2025 $-3.14 2026-02-11
Q2 2025 $-2.11 2025-11-06
Q1 2025 $-1.14 2025-08-12
FY 2025 $-1.70 2025-06-05
Q3 2025 $-6.60 2026-02-11
Q2 2025 $-4.32 2025-11-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

VIVS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
20.47 / 5.21 med
+293% premium
Net margin vs peers
-1727.8% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.